type: timeline_event
Dr. Robert Califf confirmed as FDA Commissioner by a narrow Senate vote of 50-46, highlighting ongoing concerns about pharmaceutical industry regulatory capture. Historical evidence suggests a systemic 'revolving door' between FDA and pharmaceutical companies, with approximately 27% of drug reviewers transitioning to industry roles. This pattern creates significant potential conflicts of interest and undermines regulatory oversight capabilities.